Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Investor's Business Daily on MSN
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved ...
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.
Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...
Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...
UN World Children's Day on Nov 20 is an annual reminder that every child deserves the chance not just to survive, but to ...
A “game-changing” injection to prevent HIV is set to be approved for use in England and Wales. The long-acting cabotegravir ...
The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in 2023. This is despite growing availability of a highly effective HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback